Evotec and Vifor Pharma form joint venture

07-Nov-2019 - Evotec SE and Vifor Pharma announced the launch of a 50:50 joint venture focused on the discovery and development of novel nephrology therapeutics. Vifor Pharma will be benefiting from access to an external R&D capability for the development of its own nephrology pipeline, while Evotec will gain ...

New management at Vifor Pharma and new Galenica Group CFO designated

07-Oct-2016 - The Board of Directors of the Galenica Group has designated Stefan Schulze, currently CEO of Vifor Fresenius Medical Care Renal Pharma (VFMCRP), as Chief Operating Officer (COO) and President of the Executive Committee of Vifor Pharma. Under the proven leadership of the Executive Chairman of the ...

Vifor Fresenius Medical Care Renal Pharma and Relypsa enter into partnership to commercialize Patiromer FOS

12-Aug-2015 - Vifor Fresenius Medical Care Renal Pharma Ltd. announced they have entered into an exclusive partnership to commercialize Patiromer for Oral Suspension (Patiromer FOS), Relypsa's investigational medicine for the treatment of hyperkalemia. Under the terms of the agreement, Relypsa will receive an ...

CellCept reaches positive results in Phase III trial in Lupus Nephritis

07-Jun-2010 - Vifor Pharma, the pharma business sector of the Galenica Group, and Roche announced that the maintenance phase of the Aspreva Lupus Management Study (ALMS) has successfully achieved its primary endpoint. The trial demonstrates the superiority of Roche’s CellCept (mycophenolate mofetil) versus ...

Evotec and Vifor Pharma Sign Major Cooperation Agreement

Development of preclinical candidate in the field of anaemia

03-Feb-2010 - Evotec AG announced that it has signed an agreement with Vifor Pharma. Evotec will provide and project manage the discovery activities to identify a preclinical candidate for the treatment of anaemia. Due to confidentiality reasons both companies will not reveal further details about the ...